Vascular endothelial factor receptor 2 (VEGFR-2) is an attractive target for cancer drugs because inhibiting it prevents tumors from developing the blood vessels that they require for rapid growth.

Vascular endothelial growth factor receptor-2 (VEGFR-2) is a key regulator of tumor angiogenesis and is highly expressed in PTC, making it a promising target for therapeutic intervention. This ...

EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for LUGANO, its pivotal Phase III clinical trial. The current wet ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), today announced the Scottish Medicines Consortium (SMC) approval of LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration ...

The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal ...

Outlook Therapeutics introduces Lytenava in Germany & UK for the treatment of wet AMD: Iselin, New Jersey Tuesday, June 3, 2025, 16:00 Hrs [IST] Outlook Therapeutics, Inc., a biop ...

ISELIN, N.J., June 10, 2025(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medi ...

China NMPA accepts Hutchmed & Innovent’s NDA for fruquintinib in combo with sintilimab to treat advanced renal cell carcinoma: Hong Kong, Shanghai Friday, June 6, 2025, 09:00 Hr ...

TiNivo-2 exploratory subgroup analysis following ICI combination treatments – –  AV-380 anti-GDF15 candidate receives generic ...

The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...